Bernard Taverne, Alice Desclaux, Papa Salif Sow

More documents

Recommendations

Info

CHAPITRE I-4Vieillissement accéléré et VIHTABLEAU 1CARACTÉRISTIQUES SOCIO-DÉMOGRAPHIQUES ET CLINIQUES DES PATIENTS (N=207)ird-00718213, version 1 - 16 Jul 2012TABLEAU 2n % / Mediane (Q1-Q3)SexeMasculin 73 35.3 %Féminin 134 64.7 %Age (années) 46 (40-53)
CHAPITRE I-4Vieillissement accéléré et VIHTABLEAU 3CARACTÉRISTIQUES ANTHROPOMÉTRIQUES DES HOMMESSELON LE STATUT DE L’INFECTION À VIH (N=73)ird-00718213, version 1 - 16 Jul 2012TABLEAU 4Patients (VIH+) Contrôles (VIH-) pn % / Moy (± e.t.) n % / Moy (± e.t.)Poids (kg) 65.2 (± 12.6) 69.2 (± 14.1)Taille (cm) 175.6 (± 6.0) 174.4 (± 5.9)Indice de masse corporelle (kg/m2) 21.1 (± 3.9) 22.7 (± 4.1)Maigreur 21 28.8 11 15.1Normal 41 56.2 43 58.9Surpoids 10 13.7 16 21.9Obésité 1 1.4 3 4.1Tour de taille (cm) 81.3 (± 10.3) 80.8 (± 11.5)Tour de hanches (cm) 92.6 (± 8.4) 95.0 (± 9.6)Rapport taille-hanches 0.88 (± 0.07) 0.85 (± 0.06)Plis cutanés (mm)Bicipital 4.1 (± 2.3) 4.6 (± 2.3)Tricipital 7.9 (± 4.9) 10.9 (± 6.4)Sous-scapulaire 13.5 (± 6.3) 14.1 (± 7.4)Supra-iliaque 13.3 (± 7.7) 16.2 (± 9.8)Circonférence musculaire brachiale (cm) 27.5 (± 3.5) 28.8 (± 3.5)Indice de masse grasse (Siri) 20.0 (± 6.9) 22.1 (± 8.2)
Page 1 and 2:
ird-00718213, version 1 - 16 Jul 20
Page 3 and 4:
ird-00718213, version 1 - 16 Jul 20
Page 5 and 6:
ird-00718213, version 1 - 16 Jul 20
Page 7 and 8:
Evaluation de l’impact bio-cliniq
Page 9 and 10: ird-00718213, version 1 - 16 Jul 20
Page 11 and 12: Evaluation de l’impact bio-cliniq
Page 17 and 18: CHAPITRE I-1Mortalité : incidence,
Page 31 and 32: CHAPITRE I-2Réponse immuno-virolog
Page 41 and 42: CHAPITRE I-3Evénements indésirabl
Page 43 and 44: CHAPITRE I-3Evénements indésirabl
Page 47 and 48: CHAPITRE I-4Vieillissement accélé
Page 59: CHAPITRE I-4Vieillissement accélé
Page 67 and 68: CHAPITRE II-1Diabète et hypertensi
Page 79 and 80: CHAPITRE II-2Lipodystrophies : pré
Page 91 and 92: CHAPITRE II-3Santé sexuelle : étu
Page 103 and 104: CHAPITRE II-4L'observance au traite
Page 111 and 112:
ird-00718213, version 1 - 16 Jul 20
Page 113 and 114:
ird-00718213, version 1 - 16 Jul 20
Page 115 and 116:
CHAPITRE III-1De l’expérience de
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
ird-00718213, version 1 - 16 Jul 20
Page 127 and 128:
CHAPITRE III-2Lipodystrophies : per
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
CHAPITRE III-3Perception du risque
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
CHAPITRE III-4 Les plaintes et leur
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
CHAPITRE III-5 Typologie de l’exp
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
ird-00718213, version 1 - 16 Jul 20
Page 191 and 192:
ird-00718213, version 1 - 16 Jul 20
Page 193 and 194:
CHAPITRE IV-1Le devenir socio-écon
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
CHAPITRE IV-2Le partage du statut s
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
ird-00718213, version 1 - 16 Jul 20
Page 229 and 230:
CHAPITRE IV-3Le partage de l’info
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
ird-00718213, version 1 - 16 Jul 20
Page 239 and 240:
CHAPITRE IV-4Les attitudes en mati
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
ird-00718213, version 1 - 16 Jul 20
Page 253 and 254:
CHAPITRE VI-5Le mariage, entre souh
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
ird-00718213, version 1 - 16 Jul 20
Page 265 and 266:
CHAPITRE IV-6L’expérience du veu
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
CHAPITRE IV-7Les personnes âgées
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
ird-00718213, version 1 - 16 Jul 20
Page 307 and 308:
CHAPITRE V-1Perceptions et prise en
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
ird-00718213, version 1 - 16 Jul 20
Page 319 and 320:
CHAPITRE V-2Dispositif institutionn
Page 321 and 322:
Page 323 and 324:
Page 325 and 326:
Page 327 and 328:
ird-00718213, version 1 - 16 Jul 20
Page 329 and 330:
CHAPITRE V-3Evolution des coûts ho
Page 331 and 332:
Page 333 and 334:
Page 335 and 336:
Page 337 and 338:
CHAPITRE V-4Du patient au réseau :
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
Page 359 and 360:
Page 361 and 362:
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
Page 369 and 370:
CHAPITRE V-5Dispositif expérimenta
Page 371 and 372:
Page 373 and 374:
Page 375 and 376:
Page 377 and 378:
Page 379 and 380:
Page 381 and 382:
Page 383 and 384:
Page 385 and 386:
Page 387 and 388:
Page 389 and 390:
ird-00718213, version 1 - 16 Jul 20
Page 391 and 392:
CHAPITRE V-6Mesurer la stigmatisati
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
Page 405 and 406:
Page 407 and 408:
ird-00718213, version 1 - 16 Jul 20
Page 409 and 410:
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
ird-00718213, version 1 - 16 Jul 20
Page 419 and 420:
ird-00718213, version 1 - 16 Jul 20
Page 421 and 422:
Dans le cadre de cette cohorte, une
Page 423 and 424:
propriété intellectuelle et la co
Page 425 and 426:
ird-00718213, version 1 - 16 Jul 20
Page 427 and 428:
VisiteSUIVI TEXTE SuiviDATE DATE Da
Page 429 and 430:
ObservanceDate d'entretien ou date
Page 431 and 432:
Mémoires et thèses réalisés à
Page 433 and 434:
Publications issues de la cohorte A
Page 435 and 436:
Page 437 and 438:
Page 439:
ird-00718213, version 1 - 16 Jul 20
show all

Bernard Taverne, Alice Desclaux, Papa Salif Sow

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?